Acorda Therapeutics Revenue 2006-2021 | ACOR

Acorda Therapeutics revenue from 2006 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Acorda Therapeutics Annual Revenue
(Millions of US $)
2020 $153
2019 $192
2018 $471
2017 $588
2016 $520
2015 $493
2014 $401
2013 $336
2012 $306
2011 $292
2010 $191
2009 $55
2008 $48
2007 $39
2006 $27
2005 $5
Acorda Therapeutics Quarterly Revenue
(Millions of US $)
2021-09-30 $31
2021-06-30 $32
2021-03-31 $29
2020-12-31 $38
2020-09-30 $53
2020-06-30 $34
2020-03-31 $28
2019-12-31 $50
2019-09-30 $48
2019-06-30 $50
2019-03-31 $44
2018-12-31 $69
2018-09-30 $143
2018-06-30 $153
2018-03-31 $106
2017-12-31 $188
2017-09-30 $141
2017-06-30 $139
2017-03-31 $119
2016-12-31 $141
2016-09-30 $136
2016-06-30 $127
2016-03-31 $116
2015-12-31 $131
2015-09-30 $148
2015-06-30 $114
2015-03-31 $100
2014-12-31 $118
2014-09-30 $106
2014-06-30 $97
2014-03-31 $81
2013-12-31 $93
2013-09-30 $85
2013-06-30 $87
2013-03-31 $72
2012-12-31 $81
2012-09-30 $77
2012-06-30 $76
2012-03-31 $71
2011-12-31 $73
2011-09-30 $93
2011-06-30 $65
2011-03-31 $61
2010-12-31 $67
2010-09-30 $64
2010-06-30 $43
2010-03-31 $18
2009-12-31 $14
2009-09-30 $15
2009-06-30 $13
2009-03-31 $12
2008-12-31 $12
2008-09-30 $12
2008-06-30 $11
2008-03-31 $12
2007-12-31 $11
2007-09-30 $10
2007-06-30 $9
2007-03-31 $8
2006-12-31 $8
2006-09-30 $6
2006-06-30 $10
2006-03-31 $4
2005-12-31 $3
2005-09-30 $3
2005-06-30 $-0
2005-03-31 $-0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.021B $0.153B
Acorda Therapeutics, Inc. is a biotechnology company developing and commercializing neurology therapies for Parkinson's disease, migraine and multiple sclerosis. Acorda has a pipeline of novel neurological therapies addressing a range of disorders, including Parkinson's disease and multiple sclerosis. Acorda markets three FDA-approved therapies, including AMPYRA? (dalfampridine) Extended Release Tablets, 10 mg.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.036B 8.91
Bio-Rad Laboratories (BIO.B) United States $17.472B 35.46
QIAGEN (QGEN) Netherlands $11.101B 18.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.210B 0.00
Emergent Biosolutions (EBS) United States $2.527B 9.09
Arcus Biosciences (RCUS) United States $2.184B 0.00
Myovant Sciences (MYOV) United Kingdom $1.260B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.080B 0.00
Zymeworks (ZYME) Canada $0.522B 0.00
SQZ Biotechnologies (SQZ) United States $0.201B 0.00
Ambrx Biopharma (AMAM) United States $0.191B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.81